Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping
JACC: Heart Failure · 2024-03 · 12 (3) · 451-460
DOI: 10.1016/j.jchf.2023.11.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JACC: Heart Failure, 2024-03. Verfasst von Matthew G Dimond und 17 weiteren Autor:innen. Beteiligte Einrichtung: Inova Schar Heart and Vascular, Falls Church, Virginia, USA. Hauptthemen laut MEDLINE: Ventricular Function, Left, Heart Failure. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FDA HHS, U.S. Food and Drug Administration.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Heart failure (HF) is a complex syndrome traditionally classified by left ventricular ejection fraction (LVEF) cutpoints. Although LVEF is prognostic for risk of events and predictive of response to some HF therapies, LVEF is a continuous variable and cutpoints are arbitrary, often based on historical clinical trial enrichment decisions rather than physiology. Holistic evaluation of the treatment effects for therapies throughout the LVEF range suggests the standard categorization paradigm for HF merits modification. The multidisciplinary Heart Failure Collaboratory reviewed data from large-scale HF clinical trials and found that many HF therapies have demonstrated therapeutic benefit across a large range of LVEF, but specific treatment effects vary across that range. Therefore, HF should practically be classified by association with an LVEF that is reduced or not reduced, while acknowledging uncertainty around the precise LVEF cutpoint, and future research should evaluate new therapies across the continuum of LVEF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Inova Schar Heart and Vascular, Falls Church, Virginia, USA.
- Duke University Medical Center, Durham, North Carolina, USA.
- British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
- Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
- Yale University School of Medicine, New Haven, Connecticut, USA.
- Baylor College of Medicine, Houston, Texas, USA.
Förderung
- FDA HHS
- U.S. Food and Drug Administration
Zitieren
APA
Dimond, M. G., Ibrahim, N. E., Fiuzat, M., McMurray, J. J. V., Lindenfeld, J., Ahmad, T., Bozkurt, B., Bristow, M. R., Butler, J., Carson, P. E., Felker, G. M., Jessup, M., Murillo, J., Kondo, T., Solomon, S. D., Abraham, W. T., O'Connor, C. M., & Psotka, M. A. (2024). Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping. JACC: Heart Failure, 12(3), 451-460. https://doi.org/10.1016/j.jchf.2023.11.005
Vancouver
Dimond MG, Ibrahim NE, Fiuzat M, McMurray JJV, Lindenfeld J, Ahmad T, et al. Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping. JACC: Heart Failure. 2024;12(3):451-460. doi:10.1016/j.jchf.2023.11.005
BibTeX
@article{Dimond2024,
author = {Dimond, Matthew G and Ibrahim, Nasrien E and Fiuzat, Mona and McMurray, John J V and Lindenfeld, JoAnn and Ahmad, Tariq and Bozkurt, Biykem and Bristow, Michael R and Butler, Javed and Carson, Peter E and Felker, G Michael and Jessup, Mariell and Murillo, Jaime and Kondo, Toru and Solomon, Scott D and Abraham, William T and O'Connor, Christopher M and Psotka, Mitchell A},
title = {Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping},
journal = {JACC: Heart Failure},
year = {2024},
volume = {12},
number = {3},
pages = {451--460},
doi = {10.1016/j.jchf.2023.11.005}
}
EUVIMED